CA2691107A1 - Pharmaceutical combination of nsaid and prostaglandin compound - Google Patents

Pharmaceutical combination of nsaid and prostaglandin compound Download PDF

Info

Publication number
CA2691107A1
CA2691107A1 CA2691107A CA2691107A CA2691107A1 CA 2691107 A1 CA2691107 A1 CA 2691107A1 CA 2691107 A CA2691107 A CA 2691107A CA 2691107 A CA2691107 A CA 2691107A CA 2691107 A1 CA2691107 A1 CA 2691107A1
Authority
CA
Canada
Prior art keywords
prostaglandin
compound
combination
dihydro
keto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2691107A
Other languages
English (en)
French (fr)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2691107A1 publication Critical patent/CA2691107A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2691107A 2007-07-03 2008-07-03 Pharmaceutical combination of nsaid and prostaglandin compound Abandoned CA2691107A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92955707P 2007-07-03 2007-07-03
US60/929,557 2007-07-03
US3751708P 2008-03-18 2008-03-18
US61/037,517 2008-03-18
PCT/JP2008/062437 WO2009005172A1 (en) 2007-07-03 2008-07-03 Pharmaceutical combination of nsaid and prostaglandin compound

Publications (1)

Publication Number Publication Date
CA2691107A1 true CA2691107A1 (en) 2009-01-08

Family

ID=39863290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2691107A Abandoned CA2691107A1 (en) 2007-07-03 2008-07-03 Pharmaceutical combination of nsaid and prostaglandin compound

Country Status (13)

Country Link
US (1) US20090012165A1 (enExample)
EP (1) EP2175861B1 (enExample)
JP (1) JP2010532314A (enExample)
KR (1) KR20100056445A (enExample)
CN (1) CN101686984A (enExample)
AU (1) AU2008271982B2 (enExample)
BR (1) BRPI0812838A2 (enExample)
CA (1) CA2691107A1 (enExample)
IL (1) IL202765A0 (enExample)
NZ (1) NZ582327A (enExample)
RU (1) RU2010103505A (enExample)
SG (1) SG182236A1 (enExample)
WO (1) WO2009005172A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
CN102985443B (zh) 2010-04-16 2017-05-10 动量制药公司 组织靶向
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
EP3003324A4 (en) 2013-05-28 2017-01-25 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781429A (en) * 1972-09-29 1973-12-25 American Cyanamid Co Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
CA1041012A (en) * 1973-07-10 1978-10-24 American Home Products Corporation Method of reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammotory drugs and compositions therefor
ZA748216B (en) * 1974-01-28 1976-01-28 Upjohn Co Medical treatment with prostaglandins
US3928588A (en) * 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US5428062A (en) * 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
US5225439A (en) * 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
DK0650361T3 (da) * 1992-06-30 1999-06-23 Procter & Gamble Pharma Sammensætninger til behandling af arthritis, hvilke sammensætninger indeholder phosphonater og NSAID'er
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
US5876034A (en) 1997-12-17 1999-03-02 Stafford; James R. Sporting fishing board game
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
ATE402925T2 (de) 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
CA2458471C (en) * 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
ES2591252T3 (es) * 2002-12-27 2016-11-25 Sucampo Ag Derivados de prostaglandinas para tratar el síndrome de colon irritable y/o la dispepsia funcional
KR20140069182A (ko) * 2005-04-12 2014-06-09 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자 펌프 억제제의 병용
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
EP2026651B1 (en) * 2006-03-08 2013-04-17 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
EP2059247A1 (en) * 2006-09-06 2009-05-20 Sucampo AG Method and composition for promoting gastrointestinal bicarbonate secretion
EP2465506A1 (en) * 2006-12-18 2012-06-20 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders

Also Published As

Publication number Publication date
NZ582327A (en) 2012-08-31
WO2009005172A1 (en) 2009-01-08
EP2175861A1 (en) 2010-04-21
EP2175861B1 (en) 2014-08-20
BRPI0812838A2 (pt) 2014-12-09
SG182236A1 (en) 2012-07-30
US20090012165A1 (en) 2009-01-08
RU2010103505A (ru) 2011-08-10
CN101686984A (zh) 2010-03-31
JP2010532314A (ja) 2010-10-07
AU2008271982A1 (en) 2009-01-08
IL202765A0 (en) 2010-06-30
KR20100056445A (ko) 2010-05-27
AU2008271982B2 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
AU2008271982B2 (en) Pharmaceutical combination of NSAID and prostaglandin compound
US20100298424A1 (en) Method for treating abdominal discomfort
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
CA2602812C (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
US10561649B2 (en) Pharmaceutical combination of opioid and prostaglandin compound
US20110034424A1 (en) Method for the long term nsaid use
AU2010296307A1 (en) Pharmaceutical combination for treating tumor
WO2013161973A1 (en) Method for treating irritable bowel syndrome with diarrhea

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130625

FZDE Discontinued

Effective date: 20160302